A dose escalation study of CT-2106 administered for three consecutive weeks on a 4-week cycle for patients with solid tumors
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2005
At a glance
- Drugs CT 2106 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 18 Nov 2005 New trial record.